Literature DB >> 29113189

The oncogenic transcription factor ERG represses the transcription of the tumour suppressor gene PTEN in prostate cancer cells.

Patricia Adamo1, Sean Porazinski1, Shavanthi Rajatileka1, Samantha Jumbe1, Rachel Hagen1, Man-Kim Cheung1, Ian Wilson1, Michael R Ladomery1.   

Abstract

The oncogene ETS-related gene (ERG) encodes a transcription factor with roles in the regulation of haematopoiesis, angiogenesis, vasculogenesis, inflammation, migration and invasion. The ERG oncogene is activated in >50% of prostate cancer cases, generally through a gene fusion with the androgen-responsive promoter of transmembrane protease serine 2. Phosphatase and tensin homologue (PTEN) is an important tumour suppressor gene that is often inactivated in cancer. ERG overexpression combined with PTEN inactivation or loss is often associated with aggressive prostate cancer. The present study aimed to determine whether or not ERG regulates PTEN transcription directly. ERG was demonstrated to bind to the PTEN promoter and repress its transcription. ERG overexpression reduced endogenous PTEN expression, whereas ERG knockdown increased PTEN expression. The ability of ERG to repress PTEN may contribute to a more cancer-permissive environment.

Entities:  

Keywords:  ERG; PTEN; TMPRSS2 fusion; prostate cancer

Year:  2017        PMID: 29113189      PMCID: PMC5654480          DOI: 10.3892/ol.2017.6841

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  26 in total

Review 1.  Molecular genetics of prostate cancer.

Authors:  C Abate-Shen; M M Shen
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

2.  Determinants of DNA-binding specificity of ETS-domain transcription factors.

Authors:  P Shore; A J Whitmarsh; R Bhaskaran; R J Davis; J P Waltho; A D Sharrocks
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

3.  Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.

Authors:  Jintang He; Xuefei Sun; Tujin Shi; Athena A Schepmoes; Thomas L Fillmore; Vladislav A Petyuk; Fang Xie; Rui Zhao; Marina A Gritsenko; Feng Yang; Naoki Kitabayashi; Sung-Suk Chae; Mark A Rubin; Javed Siddiqui; John T Wei; Arul M Chinnaiyan; Wei-Jun Qian; Richard D Smith; Jacob Kagan; Sudhir Srivastava; Karin D Rodland; Tao Liu; David G Camp
Journal:  Mol Oncol       Date:  2014-02-21       Impact factor: 6.603

4.  Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer.

Authors:  Antje Krohn; Fabian Freudenthaler; Silvia Harasimowicz; Martina Kluth; Sarah Fuchs; Lia Burkhardt; Phillip Stahl; Maria C Tsourlakis; Melanie Bauer; Pierre Tennstedt; Markus Graefen; Stefan Steurer; Hueseyin Sirma; Guido Sauter; Thorsten Schlomm; Ronald Simon; Sarah Minner
Journal:  Mod Pathol       Date:  2014-04-25       Impact factor: 7.842

5.  The use of real-time quantitative PCR to detect circulating prostate-specific membrane antigen mRNA in patients with prostate carcinoma.

Authors:  Da-Chang Chu; Cheng-Keng Chuang; Yi-Fang Liou; Ron-Dar Tzou; Hsiao-Chun Lee; Chien-Feng Sun
Journal:  Ann N Y Acad Sci       Date:  2004-06       Impact factor: 5.691

6.  TMPRSS2-ERG and PTEN loss in prostate cancer.

Authors:  Jeremy A Squire
Journal:  Nat Genet       Date:  2009-05       Impact factor: 38.330

7.  The evolving biology and treatment of prostate cancer.

Authors:  Russel S Taichman; Robert D Loberg; Rohit Mehra; Kenneth J Pienta
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

8.  Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Authors:  Rajareddy Singareddy; Louie Semaan; M Katie Conley-Lacomb; Jason St John; Katelyn Powell; Matthew Iyer; Daryn Smith; Lance K Heilbrun; Dongping Shi; Wael Sakr; Michael L Cher; Sreenivasa R Chinni
Journal:  Mol Cancer Res       Date:  2013-08-05       Impact factor: 5.852

Review 9.  Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer.

Authors:  Chandan Kumar-Sinha; Arul M Chinnaiyan
Journal:  Urology       Date:  2003-12-29       Impact factor: 2.649

10.  ERG induces a mesenchymal-like state associated with chemoresistance in leukemia cells.

Authors:  Liliana H Mochmann; Martin Neumann; Eva K von der Heide; Verena Nowak; Anja A Kühl; Jutta Ortiz-Tanchez; Juliane Bock; Wolf K Hofmann; Claudia D Baldus
Journal:  Oncotarget       Date:  2014-01-30
View more
  4 in total

1.  C-MYC, HIF-1α, ERG, TKT, and GSTP1: an Axis in Prostate Cancer?

Authors:  L Boldrini; R Bartoletti; M Giordano; F Manassero; C Selli; M Panichi; L Galli; F Farci; P Faviana
Journal:  Pathol Oncol Res       Date:  2018-10-25       Impact factor: 3.201

2.  Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.

Authors:  Sean Porazinski; Michael Ladomery; Ling Li; Lisa Hobson; Laura Perry; Bethany Clark; Susan Heavey; Aiman Haider; Ashwin Sridhar; Greg Shaw; John Kelly; Alex Freeman; Ian Wilson; Hayley Whitaker; Elmar Nurmemmedov; Sebastian Oltean
Journal:  Br J Cancer       Date:  2020-06-25       Impact factor: 7.640

3.  Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer.

Authors:  Andreas Marx; Andreas M Luebke; Till S Clauditz; Stefan Steurer; Christoph Fraune; Claudia Hube-Magg; Franziska Büscheck; Doris Höflmayer; Maria Christina Tsourlakis; Christina Möller-Koop; Ronald Simon; Guido Sauter; Cosima Göbel; Patrick Lebok; David Dum; Simon Kind; Sarah Minner; Jakob Izbicki; Thorsten Schlomm; Hartwig Huland; Hans Heinzer; Eike Burandt; Alexander Haese; Markus Graefen; Jan Meiners
Journal:  Dis Markers       Date:  2020-04-25       Impact factor: 3.434

4.  Ras/ERK and PI3K/AKT signaling differentially regulate oncogenic ERG mediated transcription in prostate cells.

Authors:  Brady G Strittmatter; Travis J Jerde; Peter C Hollenhorst
Journal:  PLoS Genet       Date:  2021-07-27       Impact factor: 6.020

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.